Commerce Bank’s Protalix BioTherapeutics PLX Stock Holding History

Commerce Bank’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-1,000	Closed	-$2K	–	995
2019 Q3	$2K	Hold	1,000	–	–	﹤0.01%	930
2019 Q2	$5K	Hold	1,000	–	–	﹤0.01%	917
2019 Q1	$4K	Hold	1,000	–	–	﹤0.01%	880
2018 Q4	$3K	Hold	1,000	–	–	﹤0.01%	850
2018 Q3	$7K	Hold	1,000	–	–	﹤0.01%	867
2018 Q2	$4K	Hold	1,000	–	–	﹤0.01%	856
2018 Q1	$5K	Hold	1,000	–	–	﹤0.01%	836
2017 Q4	$7K	Hold	1,000	–	–	﹤0.01%	830
2017 Q3	$6K	Hold	1,000	–	–	﹤0.01%	817
2017 Q2	$8K	Buy	+1,000	New	+$9.39K	﹤0.01%	820

Other funds holding PLX

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

MWPCG

Measured Wealth Private Client Group Portsmouth, New Hampshire $366M AUM 21.68% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Commerce Bank's PLX Position: Q4 2019 in Review

Commerce Bank sold out of Protalix BioTherapeutics (PLX) in Q4 2019, closing a stake of 1,000 shares — an estimated $2K sold.

Commerce Bank first reported a position in PLX in Q2 2017 and held it in 10 quarters. The position peaked at $8K in Q2 2017. 15 funds tracked by Wall St. Rank hold PLX as of Q4 2019.

Commerce Bank reported no remaining Protalix BioTherapeutics position as of Q4 2019 after selling out during the quarter.
Commerce Bank sold 1,000 Protalix BioTherapeutics shares in Q4 2019, an estimated $2K.
Commerce Bank first reported a position in Protalix BioTherapeutics in Q2 2017 and held it in 10 quarters.
Commerce Bank's Protalix BioTherapeutics position peaked at $8K in Q2 2017.
15 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q4 2019.

Based on Commerce Bank's 13F filing for Q4 2019, filed 14 Feb 2020.